English
Back
Download
Log in to access Online Inquiry
Back to the Top

Update! Watching for data! Today is Day 2!

$Monte Rosa Therapeutics (GLUE.US)$ Monte Rosa Therapeutics Announced It Will Present Preclinical Data On The Potential Of Its Highly Selective Cyclin-dependent Kinase 2 (Cdk2)-directed Molecular Glue Degrader To Treat Hr-positive/Her2-negative Breast Cancer At The 2024 San Antonio Breast Cancer Symposium
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
1373 Views
Comment
Sign in to post a comment